World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
37802
World Ranking
13441
National Ranking
6836

Overview

Sara M. Tolaney is affiliated with Harvard University in the United States and has an extensive research portfolio primarily centered on oncology and related biomedical fields.

Their recent published papers include:

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer, 2021, New England Journal of Medicine
  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer, 2021, Annals of Oncology
  • HER2-Low Breast Cancer: Pathological and Clinical Landscape, 2020, Journal of Clinical Oncology
  • Role of Immunotherapy in Triple-Negative Breast Cancer, 2020, Journal of the National Comprehensive Cancer Network
  • Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial, 2022, The Lancet Oncology

Their frequent co-authors include:

  • Nancy U. Lin
  • Elizabeth A. Mittendorf
  • Eric P. Winer
  • Hope S. Rugo
  • Nabihah Tayob

Publications by Sara M. Tolaney appear most often in the following venues:

  • Cancer Research
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Annals of Oncology
  • ESMO Open

Their main fields of study consist of:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Subfields of study include:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Radiology, Nuclear Medicine and Imaging
  • Genetics

The major topics of their research work cover:

  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Breast Cancer Treatment Studies
  • Cancer Treatment and Pharmacology
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Monoclonal and Polyclonal Antibodies Research

Best Publications

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

    Mingzhao Xing;William H. Westra;Ralph P. Tufano;Yoram Cohen

  • Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

    William M. Sikov;Donald A. Berry;Charles M. Perou;Baljit Singh

  • Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis

    Romualdo Barroso-Sousa;William T. Barry;Ana C. Garrido-Castro;F. Stephen Hodi

  • Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A Mayer;Linda T Vahdat;Sara M Tolaney

  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

    Sara M. Tolaney;William T. Barry;Chau T. Dang;Denise A. Yardley

  • Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

    Ayca Gucalp;Ayca Gucalp;Sara Tolaney;Steven J. Isakoff;James N. Ingle

  • Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors

    Viktor A. Adalsteinsson;Viktor A. Adalsteinsson;Gavin Ha;Gavin Ha;Samuel S. Freeman;Samuel S. Freeman;Atish D. Choudhury

  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer†

    A. Gennari;F. André;C.H. Barrios;J. Cortés

  • Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

    Amita Patnaik;Lee S. Rosen;Sara M. Tolaney;Anthony W. Tolcher

  • Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.

    Leisha A. Emens;Leisha A. Emens;Cristina Cruz;Joseph Paul Eder;Fadi Braiteh

  • MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

    Maura N. Dickler;Sara Tolaney;Hope S. Rugo;Javier Cortés

  • HER2-Low Breast Cancer: Pathological and Clinical Landscape.

    Paolo Tarantino;Paolo Tarantino;Erika Hamilton;Sara M Tolaney;Javier Cortes

  • Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A. Mayer;Jennifer R. Diamond;Rebecca L. Moroose

  • Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

    Lee-Shing Chang;Romualdo Barroso-Sousa;Sara M Tolaney;F Stephen Hodi

  • Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

    Shom Goel;Qi Wang;April C. Watt;Sara M. Tolaney

  • Role of Immunotherapy in Triple-Negative Breast Cancer

    Tanya E Keenan;Sara M Tolaney

  • Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

    Stephen R D Johnston;Nadia Harbeck;Roberto Hegg;Masakazu Toi

  • Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.

    Shaveta Vinayak;Shaveta Vinayak;Sara M. Tolaney;Lee Schwartzberg;Monica Mita

  • HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance:

    Sonia Pernas;Sara M. Tolaney

Frequent Co-Authors

Eric P. Winer
Eric P. Winer Yale University
Ian E. Krop
Ian E. Krop Harvard University
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Geoffrey I. Shapiro
Geoffrey I. Shapiro Harvard University
Lisa A. Carey
Lisa A. Carey University of North Carolina at Chapel Hill
Elizabeth A. Mittendorf
Elizabeth A. Mittendorf Brigham and Women's Hospital
Ann H. Partridge
Ann H. Partridge Harvard University
Aditya Bardia
Aditya Bardia Harvard University
Joyce O'Shaughnessy
Joyce O'Shaughnessy Baylor University Medical Center
Harold J. Burstein
Harold J. Burstein Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical careers in the USA opens many doors—not only for aspiring physicians but also for those interested in healthcare leadership, nursing, or advanced practice roles. Today, online degrees offer flexibility and a variety of pathways for students at different stages of their career journey.

For students seeking management roles, cahme-accredited online mha programs are designed to help you build leadership skills in healthcare administration with trusted accreditation. Nursing professionals looking to advance their education conveniently might consider the best online rn to bsn programs without clinical requirements, which make earning a bachelor’s degree more accessible for working RNs.

For those who wish to pursue the highest level of clinical practice, both expedited and cost-effective options are available. Prospective students can research the quickest dnp program to accelerate their timeline, or prioritize value with affordable dnp programs. These flexible options make it easier to progress professionally while balancing other responsibilities.

Best Scientists Citing Sara M. Tolaney

Trending Scientists

Recently Published Articles